| ²é¿´: 825 | »Ø¸´: 0 | |||
sports5233Òø³æ (СÓÐÃûÆø)
|
[½»Á÷]
×ö¹ý¹úÍâ±ÇÅç¼ÁÏîÄ¿µÄ½ø£¡
|
|
¸÷λ´óϺ£¬±¾ÈËÓм¸¸ö¹ØÓÚ»ìÐüÐͱÇÅç¼ÁµÄÎÊÌâÏëºÍ´ó¼Ò½»Á÷һϣº 1 ¶ÔÓÚ»ìÐüÐͱÇÅç¼Á£¬FDAÒªÇóÊÇÌåÄÚÌåÍâBE¾ùÒªÇó×ö£¬µ«¾Ísystemic exposure and systemic absorptionÕâ¶þÕßµÄÇø±ðÊÇʲô£¿ 2 »ìÐüÐͱÇÅç¼Á£¬Å·ÖÞÊÇÒªÇó×öÌåÄÚBEÂ𣿡°if possible pharmacodynamic studies or local availability studies; possibly in vitro studies or argumentation in case of minor differences. Otherwise clinical studies. Any safety issue has to be addressed appropriately¡±£¬ÕâÊÇ·¨¹æÖеÄÔ»°£¬ÔõôÀí½âÄØ£¿¹Ø¼ü¾ÍÊÇPD»ò¾Ö²¿ÀûÓöȣ¬ÌåÍâÑо¿ºÍ²îÒìÌÖÂÛ£¬»¹ÓÐÁÙ´²ÊÔÑ飬ÊÇǰÁ½ÏîÊÇÒ»¼¶¶øÁÙ´²ÊÇÒ»¼¶ÄØ£¬»¹ÊÇÕâÈýÏî¸÷×ÔÊÇÒ»¼¶µÄ²¢ÁйØÏµÄØ£¿ 3 ËÓÐÈÕ±¾±ÇÅç¼ÁµÄÖ¸µ¼ÔÔò°¡£¿ Íû¶à½»Á÷°¡£¡ |
» ²ÂÄãϲ»¶
ÖØÇìÒ½¿Æ´óѧ-È˹¤ÖÇÄÜҽѧѧԺ
ÒѾÓÐ0È˻ظ´
ÖØÇìÒ½¿Æ´óѧ-È˹¤ÖÇÄÜҽѧѧԺ
ÒѾÓÐ1È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ118È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
SUES&NERCN¿ÎÌâ×é½ÓÊÜ˶ʿÉúµ÷¼Á (ѧ˶1Ãû+ר˶1Ãû)
ÒѾÓÐ0È˻ظ´
ÀöˮѧԺ²ÄÁÏÓëÄÜÔ´¹¤³ÌѧԺÕÐÊÕµ÷¼Á£¡£¨¿Éµ÷¼Áרҵ·¶Î§¹ã£©
ÒѾÓÐ0È˻ظ´
Çç´¨ÍòÀïÐÂÊé
ÒѾÓÐ4È˻ظ´
ÔÚÏßÇóÖú£¬¼±£¡£¡£¡ÇëÎÊÄÄÀï¿ÉÒÔ×ö´ÅÐÔÄÉÃײÄÁϵĸ߷ֱæÍ¸Éäµç¾µµÄ²âÊÔ±íÕ÷ѽ£¿
ÒѾÓÐ5È˻ظ´
Çó´óÀÐÊÕÁô
ÒѾÓÐ0È˻ظ´
¸£ÖÝ´óѧÀîÐËÊç½ÌÊÚ¿ÎÌâ×é¼±Õв©Ê¿Ñо¿Éú
ÒѾÓÐ9È˻ظ´
Liquid Chromatography-Mass Spectrometry Analysis of Small Interfering RNAs
ÒѾÓÐ1È˻ظ´
ÕÒµ½Ò»Ð©Ïà¹ØµÄ¾«»ªÌû×Ó£¬Ï£ÍûÓÐÓÃŶ~
ÇóÖú£º±Ç×Ó¸ÉÔ°®´òÅçÌçÔõô°ì
ÒѾÓÐ14È˻ظ´
¿ÆÑдÓСľ³æ¿ªÊ¼£¬ÈËÈËΪÎÒ£¬ÎÒΪÈËÈË











»Ø¸´´ËÂ¥
µã»÷ÕâÀïËÑË÷¸ü¶àÏà¹Ø×ÊÔ´
5